Leucovorin, 5-fluorouracil, and gemcitabine: A phase I study
- 1 February 1999
- journal article
- clinical trial
- Published by Springer Nature in Investigational New Drugs
- Vol. 17 (1) , 57-61
- https://doi.org/10.1023/a:1006239200772
Abstract
Gemcitabine is a chemotherapy agent with efficacy in the treatment of lung, pancreas, bladder and breast cancer. It inhibits DNA synthesis by interfering with cytidine triphosphate production and...Keywords
This publication has 20 references indexed in Scilit:
- A phase I study of gemcitabine, 5-fluorouracil and leucovorin in patients with advanced, recurrent, and/or metastatic solid tumorsInvestigational New Drugs, 1998
- Cytotoxicity and DNA fragmentation associated with sequential gemcitabine and 5-fluoro-2'-deoxyuridine in HT-29 colon cancer cells.1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Gemcitabine: metabolism, mechanisms of action, and self-potentiation.1995
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreasInvestigational New Drugs, 1994
- 2'-Deoxy-2'-methylenecytidine and 2'-deoxy-2',2'-difluorocytidine 5'-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductaseJournal of Medicinal Chemistry, 1991
- INHIBITION OF RIBONUCLEOTIDE REDUCTION IN CCRF-CEM CELLS BY 2',2'-DIFLUORODEOXYCYTIDINE1990
- 5-Fluorouracil (FUra)Pharmacology & Therapeutics, 1984
- Therapeutic response of leukemic mice treated with fluorinated pyrimidines and inhibitors of deoxyuridylate synthesisBiochemical Pharmacology, 1982